Cancer Registry (ACR). Patients were stratified into 2 cohorts: those with (1) node-negative disease who received DCH or TCH or (2) node-positive disease who received FEC-DH or TCH ( Figure 1 ). Patient and pathology characteristics (Tables 1 and 2
Search Results
Zachary Veitch, Omar F. Khan, Derek Tilley, Domen Ribnikar, Xanthoula Kostaras, Karen King, Patricia Tang, and Sasha Lupichuk
Karen L. Rech and Rong He
conditions. The diagnosis requires multidisciplinary integration of the entire picture from the clinical, radiology, laboratory, and pathology perspectives. Clinical Presentation The presenting signs and symptoms of histiocytic neoplasms are diverse, and
Silviya K. Meletath, Dean Pavlick, Tim Brennan, Roy Hamilton, Juliann Chmielecki, Julia A. Elvin, Norma Palma, Jeffrey S. Ross, Vincent A. Miller, Philip J. Stephens, George Snipes, Veena Rajaram, Siraj M. Ali, and Isaac Melguizo-Gavilanes
pathology report noted features of ganglioglioma with mixed neuronal and glial growth patterns. In regions of the tumor with an abundant glial component, there was evidence of moderate cell proliferation as assessed by Ki-67 (MIB-1) immunohistochemistry (A
Presenters: Chad A. LaGrange, M. Dror Michaelson, and Colleen H. Tetzlaff
nephrectomy. Pathology report revealed pT3a clear-cell RCC, Furhman grade 4, and no sarcomatoid or rhabdoid features. In March 2019, CT of the chest revealed an increase in lung nodules up to 15 mm. CT-guided lung biopsy in May 2019 was consistent with
Wui-Jin Koh, Benjamin E. Greer, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, John Chan, Kathleen R. Cho, David Cohn, Marta Ann Crispens, Nefertiti DuPont, Patricia J. Eifel, Amanda Nickles Fader, Christine M. Fisher, David K. Gaffney, Suzanne George, Ernest Han, Warner K. Huh, John R. Lurain III, Lainie Martin, David Mutch, Steven W. Remmenga, R. Kevin Reynolds, William Small Jr, Nelson Teng, Todd Tillmanns, Fidel A. Valea, Nicole McMillian, and Miranda Hughes
suspected uterine neoplasms, the initial evaluation/workup includes a history and physical examination, endometrial biopsy, and other studies (see UN-1, page 250). 7 An expert pathology review will determine whether a patient has either 1) a malignant
Mod C. Chandhanayingyong, Nicholas M. Bernthal, Piti Ungarreevittaya, Scott D. Nelson, Sant P. Chawla, and Arun S. Singh
. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease . Hum Mol Genet 1997 ; 6 : 1383 – 1387 . 3 Starink TM Hausman R . The cutaneous pathology of extrafacial lesions in Cowden's disease . J Cutan Pathol 1984 ; 11 : 338
Lara Franziska Stolzenbach, Giuseppe Rosiello, Angela Pecoraro, Carlotta Palumbo, Stefano Luzzago, Marina Deuker, Zhe Tian, Anne-Sophie Knipper, Raisa Pompe, Kevin C. Zorn, Shahrokh F. Shariat, Felix K.H. Chun, Markus Graefen, Fred Saad, and Pierre I. Karakiewicz
final pathology at RP; the rates of upstaging, defined as a non–organ-confined tumor (stage pT3+/pN1) at RP; and the rates of upgrading and/or upstaging, defined as a combination of both, were tabulated for Black and White patients. Specifically, 3
NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021
Featured Updates to the NCCN Guidelines
Nadeem R. Abu-Rustum, Catheryn M. Yashar, Kristin Bradley, Susana M. Campos, Junzo Chino, Hye Sook Chon, Christina Chu, David Cohn, Marta Ann Crispens, Shari Damast, Elisabeth Diver, Christine M. Fisher, Peter Frederick, David K. Gaffney, Suzanne George, Robert Giuntoli II, Ernest Han, Brooke Howitt, Warner K. Huh, Jayanthi Lea, Andrea Mariani, David Mutch, Larissa Nekhlyudov, Mirna Podoll, Steven W. Remmenga, R. Kevin Reynolds, Ritu Salani, Rachel Sisodia, Pamela Soliman, Edward Tanner, Stefanie Ueda, Renata Urban, Stephanie L. Wethington, Emily Wyse, Kristine Zanotti, Nicole R. McMillian, and Angela D. Motter
of Pathology and Molecular Analysis section of the Uterine Sarcoma Guidelines in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Uterine Neoplasms. In addition to the introductory page ( UTSARC-A 1 of 5 , above), this section
Michael Cecchini, Jeffrey Sklar, and Jill Lacy
neoadjuvant FOLFIRINOX followed by pancreaticoduodenectomy with negative margins and 6 cycles of adjuvant FOLFIRINOX. Surgical pathology revealed ypT3N1Mx (stage IIB) adenocarcinoma. Eight months after completion of adjuvant therapy, PET imaging revealed
Michael A. Cilento, Nicola K. Poplawski, Sellvakumaram Paramasivam, David M. Thomas, and Ganessan Kichenadasse
tumor from the diaphragm and Gerota fascia. There was no evidence of disease on postoperative imaging. Surgical pathology showed a high-grade serous carcinoma of endometrial origin with the bulk of the tumor arising from the lower fundus, lower uterine
